Literature DB >> 19322925

Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.

Ni Dai1, Ai-Ping Lu, Cheng-Chao Shou, Ji-You Li.   

Abstract

AIM: To investigate the prognostic significance of phosphatase regenerating liver 3 (PRL-3) protein expression in gastric cancer.
METHODS: PRL-3 expression in paraffin-embedded tumor specimens from 293 patients with gastric cancer was studied retrospectively by immunohistochemistry. Monoclonal antibody specifically against PRL-3, 3B6, was obtained with hybridoma technique.
RESULTS: Positive PRL-3 expression was detected in 43.3% (127 of 293) of gastric cancer cases. High expression of PRL-3 was positively correlated with tumor size, depth of invasion, vascular/lymphatic invasion, lymph node metastasis, high TNM stage and tumor recurrence. Patients with positive PRL-3 expression had a significantly lower 5-year survival rate than those with negative expression (28.3% vs 51.9%, P < 0.0001). Patients who received curative surgery, and with positive PRL-3 expression had a significant shorter overall survival and disease-free disadvantage over patients with negative expression (hazard ratio of 16.7 and 16.6, respectively; P < 0.0001 for both). Multivariate analysis revealed that PRL-3 expression was an independent prognostic indicator for overall and disease-free survival of gastric cancer patients, particularly for survival in TNM stage III patients.
CONCLUSION: PRL-3 expression is a new independent prognostic indicator to predict the potential of recurrence and survival in patients with gastric cancer at the time of tumor resection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19322925      PMCID: PMC2665146          DOI: 10.3748/wjg.15.1499

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

1.  Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome.

Authors:  Q Zeng; X Si; H Horstmann; Y Xu; W Hong; C J Pallen
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 2.  The lamellipodium: where motility begins.

Authors:  J Victor Small; Theresia Stradal; Emmanuel Vignal; Klemens Rottner
Journal:  Trends Cell Biol       Date:  2002-03       Impact factor: 20.808

3.  Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling.

Authors:  W F Matter; T Estridge; C Zhang; R Belagaje; L Stancato; J Dixon; B Johnson; L Bloem; T Pickard; M Donaghue; S Acton; R Jeyaseelan; V Kadambi; C J Vlahos
Journal:  Biochem Biophys Res Commun       Date:  2001-05-25       Impact factor: 3.575

4.  Structural insights into molecular function of the metastasis-associated phosphatase PRL-3.

Authors:  Guennadi Kozlov; Jing Cheng; Edmund Ziomek; Denis Banville; Kalle Gehring; Irena Ekiel
Journal:  J Biol Chem       Date:  2004-01-01       Impact factor: 5.157

5.  A phosphatase associated with metastasis of colorectal cancer.

Authors:  S Saha; A Bardelli; P Buckhaults; V E Velculescu; C Rago; B St Croix; K E Romans; M A Choti; C Lengauer; K W Kinzler; B Vogelstein
Journal:  Science       Date:  2001-10-11       Impact factor: 47.728

6.  Analysis of stromal-epithelial interactions in prostate cancer identifies PTPCAAX2 as a potential oncogene.

Authors:  Qin Wang; David I R Holmes; Sue M Powell; Qi L Lu; Jonathan Waxman
Journal:  Cancer Lett       Date:  2002-01-10       Impact factor: 8.679

7.  PRL-3 expression in metastatic cancers.

Authors:  Alberto Bardelli; Saurabh Saha; Jason A Sager; Kathy E Romans; Baozhong Xin; Sanford D Markowitz; Christoph Lengauer; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

8.  PRL-3 and PRL-1 promote cell migration, invasion, and metastasis.

Authors:  Qi Zeng; Jing-Ming Dong; Ke Guo; Jie Li; Hui-Xian Tan; Vicki Koh; Catherine J Pallen; Edward Manser; Wanjin Hong
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

9.  Pentamidine is an inhibitor of PRL phosphatases with anticancer activity.

Authors:  Manas K Pathak; Deepika Dhawan; Daniel J Lindner; Ernest C Borden; Carol Farver; Taolin Yi
Journal:  Mol Cancer Ther       Date:  2002-12       Impact factor: 6.261

Review 10.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

View more
  24 in total

Review 1.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

2.  The miR-29c-KIAA1199 axis regulates gastric cancer migration by binding with WBP11 and PTP4A3.

Authors:  Lina Wang; Ting Yu; Wei Li; Mengmeng Li; Qianfei Zuo; Quanming Zou; Bin Xiao
Journal:  Oncogene       Date:  2019-01-09       Impact factor: 9.867

3.  Adenovirus-mediated TIPE2 overexpression inhibits gastric cancer metastasis via reversal of epithelial-mesenchymal transition.

Authors:  H Yin; X Huang; M Tao; Q Hu; J Qiu; W Chen; J Wu; Y Xie
Journal:  Cancer Gene Ther       Date:  2017-02-10       Impact factor: 5.987

4.  Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer.

Authors:  Carmen M Dumaual; George E Sandusky; Han Weng Soo; Sean R Werner; Pamela L Crowell; Stephen K Randall
Journal:  Am J Transl Res       Date:  2012-01-05       Impact factor: 4.060

5.  Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.

Authors:  Zhen-Hua Sun; Ping Bu
Journal:  Exp Ther Med       Date:  2012-03-15       Impact factor: 2.447

Review 6.  Inside the human cancer tyrosine phosphatome.

Authors:  Sofi G Julien; Nadia Dubé; Serge Hardy; Michel L Tremblay
Journal:  Nat Rev Cancer       Date:  2011-01       Impact factor: 60.716

Review 7.  Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.

Authors:  Keishi Yamashita; Shinichi Sakuramoto; Masahiko Watanabe
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

Review 8.  Genomic and genetic alterations influence the progression of gastric cancer.

Authors:  Stefania Nobili; Lorenzo Bruno; Ida Landini; Cristina Napoli; Paolo Bechi; Francesco Tonelli; Carlos A Rubio; Enrico Mini; Gabriella Nesi
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

9.  PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Authors:  Min Thura; Abdul Qader Omer Al-Aidaroos; Wei Peng Yong; Koji Kono; Abhishek Gupta; You Bin Lin; Kousaku Mimura; Jean Paul Thiery; Boon Cher Goh; Patrick Tan; Ross Soo; Cheng William Hong; Lingzhi Wang; Suling Joyce Lin; Elya Chen; Sun Young Rha; Hyun Cheol Chung; Jie Li; Sayantani Nandi; Hiu Fung Yuen; Shu-Dong Zhang; Yeoh Khay Guan; Jimmy So; Qi Zeng
Journal:  JCI Insight       Date:  2016-06-16

Review 10.  Phosphatase of regenerating liver: a novel target for cancer therapy.

Authors:  Amanda M Campbell; Zhong-Yin Zhang
Journal:  Expert Opin Ther Targets       Date:  2014-03-01       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.